Literature DB >> 31205026

Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis.

Erin B Taylor1, Michael J Ryan1,2.   

Abstract

Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it is not clear how these FLCs drive renal pathology. In this issue of the JCI, Ying et al. unravel a novel mechanism by which FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney. Specifically, FLC-mediated production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1β via induction of capsase-1, and promote activation of TGF-β via αvβ6 integrin. Moreover, the authors identified a tryptophan residue within a specific monoclonal FLC that was required for optimal H2O2 production and downstream signaling. A better understanding of the drivers of MM-associated renal injury has potential for the identification of promising therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31205026      PMCID: PMC6597214          DOI: 10.1172/JCI129704

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Antibodies have the intrinsic capacity to destroy antigens.

Authors:  A D Wentworth; L H Jones; P Wentworth; K D Janda; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

Authors:  Silke Meister; Ulrich Schubert; Kirsten Neubert; Kai Herrmann; Renate Burger; Martin Gramatzki; Sabine Hahn; Sandra Schreiber; Sabine Wilhelm; Martin Herrmann; Hans-Martin Jäck; Reinhard E Voll
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

Review 5.  The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.

Authors:  Constantine S Mitsiades; Douglas W McMillin; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 6.  TGF-β signaling in the kidney: profibrotic and protective effects.

Authors:  Angara Sureshbabu; Saif A Muhsin; Mary E Choi
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-06

7.  Light chains are a ligand for megalin.

Authors:  R Bryan S Klassen; Patricia L Allen; Vecihi Batuman; Kimberly Crenshaw; Timothy G Hammond
Journal:  J Appl Physiol (1985)       Date:  2004-07-30

8.  Immunoglobulin light chains generate hydrogen peroxide.

Authors:  Pei-Xuan Wang; Paul W Sanders
Journal:  J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 10.121

9.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

Authors:  J Bladé; P Fernández-Llama; F Bosch; J Montolíu; X M Lens; S Montoto; A Cases; A Darnell; C Rozman; E Montserrat
Journal:  Arch Intern Med       Date:  1998-09-28

10.  Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

Authors:  Judith A Brebner; Robert A Stockley
Journal:  F1000 Med Rep       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.